Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Males Clear all

Conditions: Healthy
Interventions: intravenous diclofenac sodium (DIC075V), ketorolac, oral diclofenac (Cataflam), aspirin; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy Male Subjects
Interventions: 14C RPT193; Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions: Ketamine, TAK-063, TAK-063 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Creatine Absorption in Healthy Adults
Interventions: OptiCreatine, Creatine Monohydrate; Dietary Supplement
Lead sponsor: TSI Group LTD; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bacterial Infections
Interventions: XNW4107; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: [14C]-darigabat; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pharmacokinetics of ASP3662, Displacement of Radiotracer, Healthy Volunteers
Interventions: [11C]AS2471907, Positron Emission Tomography (PET), ASP3662; Other · Radiation · Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Opevesostat, Prednisone, Fludrocortisone acetate, Carbamazepine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: Mosliciguat, 14C mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: [14C]-AZD4205, single 50 mg oral dose administrated on day 1; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteer
Interventions: varegacestat; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Urinary Tract Infections
Interventions: E. coli Nissle 1917; Drug
Lead sponsor: Elizabeth Lucas; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: Q203, Placebo; Drug
Lead sponsor: Qurient Co., Ltd.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Undefined
Interventions: MyMD1, Placebo; Drug
Lead sponsor: TNF Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Healthy Participants
Interventions: BMS-986365, Rabeprazole; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: End Stage Renal Disease
Interventions: Lanthanum carbonate Granule Formulation, Lanthanum carbonate Chewable Tablets (Fosrenol); Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cypress, California

Conditions: Hepatic Impairment, Healthy
Interventions: Palovarotene; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Healthy Volunteers - Male and Female
Interventions: KP-001, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: No Evidence of Disease, Prostate Carcinoma
Interventions: Selenium, Placebo, Laboratory Biomarker Analysis, Pharmacological Study, Methylselenocysteine; Dietary Supplement · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois • Buffalo, New York • Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: [14C]AR882; Drug
Lead sponsor: Arthrosi Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Adult Male and Female Volunteers
Interventions: AVP-923; Drug
Lead sponsor: Avanir Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Respiratory Syncytial Virus Infections
Interventions: 200 mg RV521/78 µCi [ 14C]-RV521.; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Participants
Interventions: Quemliclustat; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

Study of RPT193 in Healthy Adult Male Subjects

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

Impact of OptiCreatine on Plasma Creatine and Gastrointestinal Effects in Males and Females

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

A Phase 1 Mass Balance Study of Varegacestat

Open Label Trial of Nissle 1917

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

Single Ascending-dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male Adult Subjects

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

Pharmacodynamic Study of Two Lanthanum Carbonate Formulations in Healthy Adults

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)